Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up

Eitemau Tebyg

• Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
  gan: Caorsi, R, et al.
  Cyhoeddwyd: (2011)
• The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age
  gan: Caorsi, Roberta, et al.
  Cyhoeddwyd: (2013)
• National CAPS (Cryopyrin-Associated Periodic Syndrome) Registry
  gan: Bibalo, C, et al.
  Cyhoeddwyd: (2011)
• Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
  gan: Toker, Ori, et al.
  Cyhoeddwyd: (2010)
• The interleukin 1 inhibitor canakinumab in the treatment of cryopyrin-associated periodic syndromes (CAPS): clinical experience
  gan: Svetlana Olegovna Salugina, et al.
  Cyhoeddwyd: (2014-12-01)